Literature DB >> 2543518

Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma.

H M Lewis1, W A Ratcliffe, R A Stott, M R Wilkins, P H Baylis.   

Abstract

This two-site immunoradiometric assay (IRMA) for human atrial natriuretic factor (ANF)99-126 in plasma utilizes a mouse monoclonal antibody raised against rat (r) ANF103-125 with specificity directed towards the ring structure of ANF, and a rabbit antiserum to human (h) ANF99-126. The monoclonal antibody is radioiodinated, and the IgG fraction of the antiserum is coated onto wells of a microtiter plate. Plasma or standard hANF99-126 (150 microL) is incubated with the radioligand in coated wells for 24 h. The detection limit is 0.9 pg per well, corresponding to 2 pmol/L, with a working range (CV less than 10%) from 4.5 to 540 pmol/L. Intra- and interassay precision are 7% and 9%, respectively, and the assay is unaffected by plasma matrix. In humans, the IRMA is specific for hANF99-126, the major circulating form of ANF, and does not cross-react with metabolites having deletions at the carboxy terminus. Plasma IRMA values in normal seated subjects were 6.6 +/- 1.5 (SEM) pmol/L and results correlated with those of an extraction RIA (r = 0.81, P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543518

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure.

Authors:  A Clerico; G Iervasi; M G Del Chicca; M Emdin; S Maffei; M Nannipieri; L Sabatino; F Forini; C Manfredi; L Donato
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

2.  Human pharmacokinetics of an analogue of atrial natriuretic factor.

Authors:  S H Ingwersen; H Eiskjaer; M Schmiegelow; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.